Introduction to Dordaviprone Maintenance Therapy

Managing high-risk acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) remains a formidable challenge in modern hematology. While allogeneic hematopoietic cell transplantation (HCT) offers a curative pathway, the risk of post-transplant relapse remains significantly high for patients with adverse cytogenetics. Consequently, researchers are increasingly investigating post-transplant interventions to consolidate remission and improve long-term survival. Dordaviprone maintenance therapy represents a novel approach in this setting. As a first-in-class small-molecule imipridone, dordaviprone targets specific pathways that are often dysregulated in aggressive myeloid malignancies. Historically, maintenance strategies have relied on hypomethylating agents, yet many patients still experience early recurrence. Specifically, those harboring TP53 mutations or complex karyotypes face the poorest prognoses. Therefore, the introduction of targeted agents like dordaviprone could revolutionize the standard of care for these vulnerable populations. Recent preclinical data suggested that this agent could selectively eliminate leukemia stem cells while preserving healthy bone marrow function. This selective toxicity is crucial for maintaining graft health while effectively preventing disease recurrence after the intensive conditioning and transplant process.

Challenges in Post-HCT Care for High-Risk Myeloid Neoplasms

Relapse is the primary cause of treatment failure following allogeneic HCT in patients with high-risk AML and MDS. These patients often present with features such as TP53 mutations, monosomal karyotypes, or persistent measurable residual disease (MRD) before transplantation. Despite achieving a morphologic complete remission, the subclinical persistence of resistant clones frequently leads to rapid relapse once immunosuppression is tapered. Furthermore, the toxicity associated with traditional chemotherapy limits its use in the post-HCT maintenance period. Many patients are elderly and possess limited physiological reserves, making them susceptible to prolonged cytopenias or severe graft-versus-host disease (GVHD). Thus, a clinical need exists for well-tolerated agents that do not jeopardize the donor-derived hematopoietic system. Dordaviprone maintenance therapy aims to bridge this gap by offering a manageable oral regimen. It specifically addresses the metabolic and signaling vulnerabilities of leukemia cells. By focusing on molecular drivers rather than general DNA damage, these imipridones provide a more refined therapeutic index. Ultimately, improving outcomes in this high-risk group requires strategies that can be sustained for several months without compromising the patient's quality of life.

Dordaviprone: A Dual Mechanism of Action

Dordaviprone, also known as ONC201, operates through a unique bimodal mechanism that distinguishes it from conventional kinase inhibitors or cytotoxic drugs. Primarily, it acts as a selective antagonist of the dopamine receptor D2 (DRD2), a G-protein coupled receptor that is often overexpressed in various cancers, including leukemia. By inhibiting DRD2, dordaviprone disrupts key survival signaling pathways such as Akt and ERK. Additionally, dordaviprone serves as an allosteric activator of the mitochondrial protease ClpP. When ClpP is overactivated, it leads to the degradation of essential mitochondrial proteins, resulting in the loss of oxidative phosphorylation. This metabolic catastrophe triggers the ATF4-mediated integrated stress response, eventually leading to apoptosis via the TRAIL/DR5 pathway. Interestingly, leukemia stem cells appear particularly sensitive to this mitochondrial disruption compared to normal hematopoietic stem cells. This selectivity is the foundation for using Dordaviprone maintenance therapy in the post-transplant setting. Because it does not rely on typical cell cycle checkpoints, it can effectively target quiescent malignant cells that often evade standard chemotherapy. This mechanistic precision offers hope for eradicating residual disease while maintaining a stable marrow environment.

Insights from the Phase I Clinical Trial

A Phase I clinical trial was conducted to evaluate the safety and feasibility of dordaviprone maintenance therapy in adults with high-risk AML or MDS. The study enrolled 20 participants with a median age of 68 years, reflecting the typical demographic of these diseases. The cohort included individuals with significant risk factors, including adverse-risk AML (50%) and very poor-risk MDS (75%). Notably, over a third of the patients harbored TP53 mutations, which are traditionally associated with extreme resistance to therapy. The treatment protocol involved escalating oral doses ranging from 250 mg to 625 mg, administered once weekly for up to 13 cycles. Each cycle lasted four weeks, providing a consistent maintenance window during the critical first year after HCT. Researchers aimed to determine the rate of dose-limiting toxicities (DLTs) and grade 3 or higher adverse events. Throughout the study, patients received a median of 8.5 cycles, demonstrating the practical feasibility of the oral weekly schedule. This longitudinal exposure is vital for ensuring that the drug can effectively suppress slowly proliferating malignant clones over time without causing cumulative toxicity.

Safety Profile and Tolerability Findings

The safety results from the Phase I trial are encouraging for the future of Dordaviprone maintenance therapy. Importantly, no dose-limiting toxicities or cases of graft failure were reported among the participants. This is a critical finding, as any agent used post-HCT must not interfere with the delicate balance of donor engraftment. Grade 3 or higher adverse events occurred in 45% of patients, but only 15% were considered directly related to the study drug. Severe acute GVHD (grades 3-4) was noted in only 5% of the cohort, suggesting that dordaviprone does not excessively stimulate the donor immune system to attack host tissues. Furthermore, hematologic toxicities were relatively infrequent and manageable. For instance, grade 3-4 anemia, neutropenia, and thrombocytopenia occurred in 15%, 10%, and 15% of patients, respectively. These rates are significantly lower than those observed with many other maintenance agents, such as systemic chemotherapy or certain hypomethylating agent combinations. The ability of patients to tolerate the 625 mg weekly dose suggests that this level is suitable for further clinical investigation in larger, randomized trials.

Efficacy Outcomes and Future Clinical Directions

Beyond safety, the study provided preliminary evidence of the efficacy of Dordaviprone maintenance therapy. At the two-year mark, both relapse-free survival (RFS) and overall survival (OS) were 60%. While the sample size was small, these figures are promising given the extremely high-risk nature of the study population. Specifically, many of these patients would historically be expected to relapse within the first 12 months post-transplant. The stability of the survival curves at two years suggests that dordaviprone may effectively extend the duration of remission. Consequently, these findings justify the initiation of Phase II and III trials to confirm the clinical benefit. Future research should also explore the potential synergy between dordaviprone and other targeted agents or immunotherapies. In the Indian context, where the burden of high-risk AML is significant and access to intensive salvage therapy can be limited, a well-tolerated oral maintenance option is particularly valuable. Ultimately, dordaviprone represents a significant step forward in the quest to provide durable cures for patients with the most aggressive forms of myeloid neoplasms following hematopoietic cell transplantation.

How does dordaviprone selectively target leukemia cells without damaging healthy bone marrow?

Dordaviprone utilizes a unique mechanism involving the activation of the mitochondrial protease ClpP and the inhibition of dopamine receptor D2. Leukemia stem cells frequently overexpress these targets and rely heavily on specific mitochondrial pathways for survival. By overactivating ClpP, dordaviprone causes a metabolic crisis within the malignant cells. In contrast, normal bone marrow cells possess different metabolic thresholds and signaling dependencies, allowing them to remain largely unaffected by these imipridones at therapeutic concentrations.

Is dordaviprone maintenance therapy effective for patients with the TP53 mutation?

Preliminary data from the Phase I trial indicates that dordaviprone is active against leukemia cells harboring TP53 mutations. This is particularly significant because TP53-mutated AML and MDS are notorious for their resistance to standard chemotherapy and poor outcomes post-transplant. Dordaviprone induces apoptosis through the integrated stress response and TRAIL/DR5 pathway, which can bypass some of the traditional resistance mechanisms associated with p53 dysfunction, offering a potential new strategy for these hard-to-treat genetic subgroups.

What are the primary safety concerns when using dordaviprone after a hematopoietic cell transplant?

The main safety concerns for any post-HCT maintenance agent include graft failure, severe cytopenias, and the exacerbation of graft-versus-host disease (GVHD). In clinical studies of dordaviprone, no graft failures or dose-limiting toxicities were observed. While some patients experienced grade 3 or higher adverse events, only 15% were related to the drug. Most importantly, the incidence of severe acute GVHD remained low at 5%, suggesting that dordaviprone is safe and well-tolerated in the post-transplant environment.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider regarding any medical condition. The use of specific drugs mentioned should be based on clinical judgment and the individual patient's needs. Refer to the latest local and national guidelines for clinical practice.

References

Bhatt VR et al. Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm. Am J Hematol. 2026 Jun 26. doi: 10.1002/ajh.70428. PMID: 42359621.

Prabhu VV, Morrow S, Rahman Kawakibi A, et al. ONC201 and imipridones: anti-cancer compounds with clinical efficacy. Neoplasia. 2020;22(12):725-744. doi:10.1016/j.neo.2020.09.005.

Arrillaga-Romany I, Gardner SL, Odia Y, et al. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. J Clin Oncol. 2024;42(11):1265-1274. doi:10.1200/JCO.23.01134.